MX2023014274A - Compuestos indol sustituidos y metodos de uso de los mismos. - Google Patents

Compuestos indol sustituidos y metodos de uso de los mismos.

Info

Publication number
MX2023014274A
MX2023014274A MX2023014274A MX2023014274A MX2023014274A MX 2023014274 A MX2023014274 A MX 2023014274A MX 2023014274 A MX2023014274 A MX 2023014274A MX 2023014274 A MX2023014274 A MX 2023014274A MX 2023014274 A MX2023014274 A MX 2023014274A
Authority
MX
Mexico
Prior art keywords
compounds
methods
substituted indole
indole compounds
complement
Prior art date
Application number
MX2023014274A
Other languages
English (en)
Inventor
Robert Gomez
David Andrew Powell
Tao Sheng
Jinyue Ding
Brian P Bestvater
Victoria Elizabeth Rose
Nicholas Anton Mateyko
Taro Oike
Original Assignee
Chinook Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinook Therapeutics Inc filed Critical Chinook Therapeutics Inc
Publication of MX2023014274A publication Critical patent/MX2023014274A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invención proporciona compuestos indol sustituidos. En ciertas modalidades, los compuestos son inhibidores de la vía alternativa del sistema del complemento y, en particular, inhibidores del factor B del complemento. (CFB). Además se proporcionan composiciones que comprenden los compuestos y métodos de uso de los mismos. Los compuestos proporcionados son útiles en el tratamiento, prevención o mejora de una enfermedad, afección o trastorno mediante la inhibición de la vía alternativa del complemento.
MX2023014274A 2021-06-03 2022-06-03 Compuestos indol sustituidos y metodos de uso de los mismos. MX2023014274A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163196339P 2021-06-03 2021-06-03
US202163290019P 2021-12-15 2021-12-15
US202263346120P 2022-05-26 2022-05-26
PCT/US2022/032042 WO2022256586A2 (en) 2021-06-03 2022-06-03 Substituted indole compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2023014274A true MX2023014274A (es) 2024-04-22

Family

ID=84323595

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014274A MX2023014274A (es) 2021-06-03 2022-06-03 Compuestos indol sustituidos y metodos de uso de los mismos.

Country Status (15)

Country Link
US (1) US20240287034A1 (es)
EP (1) EP4346812A2 (es)
JP (1) JP2024521878A (es)
KR (1) KR20240017004A (es)
AU (1) AU2022283903A1 (es)
BR (1) BR112023025235A2 (es)
CA (1) CA3222144A1 (es)
CL (1) CL2023003591A1 (es)
CO (1) CO2023016557A2 (es)
CR (1) CR20230564A (es)
DO (1) DOP2023000263A (es)
EC (1) ECSP23090260A (es)
IL (1) IL308835A (es)
MX (1) MX2023014274A (es)
WO (1) WO2022256586A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240090506A (ko) * 2021-10-27 2024-06-21 한서 바이오 엘엘씨 피페리디닐 인돌 유도체, 이의 제조 방법 및 의약적 용도
WO2023139534A1 (en) * 2022-01-24 2023-07-27 Novartis Ag Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof
WO2023237012A1 (zh) * 2022-06-07 2023-12-14 正大天晴药业集团股份有限公司 双环取代的芳香羧酸类氘代化合物
WO2023246677A1 (zh) * 2022-06-20 2023-12-28 深圳信立泰药业股份有限公司 一种吲哚-苯基哌啶化合物及其制备方法与应用
WO2023246870A1 (zh) * 2022-06-23 2023-12-28 上海济煜医药科技有限公司 吲哚化合物的制备、应用及用途
WO2024049977A1 (en) * 2022-08-31 2024-03-07 Chinook Therapeutics, Inc. Substituted indole compounds and methods of use thereof
WO2024051849A1 (en) * 2022-09-10 2024-03-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. 2-substituted piperidine derivatives, preparation methods and medicinal uses thereof
WO2024104292A1 (en) * 2022-11-14 2024-05-23 Novartis Pharma Ag Solid forms of complement factor b inhibitors
WO2024114677A1 (zh) * 2022-11-29 2024-06-06 上海济煜医药科技有限公司 苯并螺环吲哚化合物的制备、应用及用途
WO2024148274A1 (en) * 2023-01-05 2024-07-11 Apellis Pharmaceuticals, Inc. Complement inhibition
WO2024149261A1 (zh) * 2023-01-09 2024-07-18 南京正大天晴制药有限公司 补体因子b抑制剂
WO2024169896A1 (zh) * 2023-02-16 2024-08-22 西藏海思科制药有限公司 一种苯并氮杂芳环衍生物的盐、晶型及其在医药上的应用
WO2024175028A1 (zh) * 2023-02-22 2024-08-29 西藏海思科制药有限公司 一种苯并氮杂芳环衍生物的药物组合物及其在医药上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014002054A1 (en) * 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
ES2902006T3 (es) * 2016-06-27 2022-03-24 Achillion Pharmaceuticals Inc Quinazolina y compuestos indol para tratar trastornos médicos
EP4282486A3 (en) * 2020-08-07 2024-03-06 Shanghai Meiyue Biotech Development Co., Ltd. Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof

Also Published As

Publication number Publication date
JP2024521878A (ja) 2024-06-04
CO2023016557A2 (es) 2024-02-26
BR112023025235A2 (pt) 2024-02-27
CL2023003591A1 (es) 2024-06-28
WO2022256586A3 (en) 2023-01-12
EP4346812A2 (en) 2024-04-10
ECSP23090260A (es) 2024-02-29
AU2022283903A1 (en) 2023-11-30
KR20240017004A (ko) 2024-02-06
IL308835A (en) 2024-01-01
US20240287034A1 (en) 2024-08-29
CR20230564A (es) 2024-02-27
CA3222144A1 (en) 2022-12-08
DOP2023000263A (es) 2024-02-29
WO2022256586A2 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
MX2023014274A (es) Compuestos indol sustituidos y metodos de uso de los mismos.
CY1125022T1 (el) Μεθοδοι για θεραπεια καταστασεων που συνδυαζονται με εξαρτωμενη απο masp-2 ενεργοποιηση συμπληρωματος
CR20220642A (es) 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8
HRP20070552T3 (en) Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
MXPA05012812A (es) Compuestos, metodos y composiciones farmaceuticas para inhibir poli(adenosina-5'-difosfo-ribosa)polimerasa(parp).
ECSP066268A (es) Inhibidores de la miostatina (gdf8) en combinación con corticoesteroides para el tratamiento de desórdenes neuromusculares
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
MX2009001327A (es) Compuestos de indol.
MX2022014817A (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados.
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
SV2009003283A (es) Inhibidores de la actividad de la akt
MX2008011684A (es) Compuestos de imidazolotiazol para el tratamiento de enfermedad.
PH12021500008A1 (en) Transglutaminase 2 (tg2) inhibitors
WO2007012064A3 (en) Prevention and treatment of hearing disorders
MX2024007673A (es) Inhibidores de poli adp-ribosa polimerasas (parp1).
TW200738700A (en) HIV integrase inhibitors
MX2022003689A (es) Metodos y composiciones para el tratamiento contra una enfermedad o trastorno.
EP4365300A3 (en) Treatment/prevention of disease by linc complex inhibition
MX2021013602A (es) Inhibidores de jak.
MX2022002597A (es) Métodos de tratamiento de la epilepsia usando los métodos.
CR20220199A (es) Inhibidores del factor d del complemento para administración oral
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
PH12021551070A1 (en) Pharmaceutical composition comprising histone deacetylase 6 inhibitors
RS54185B1 (en) USE OF 24-ORDER
UA99901C2 (en) Indole compounds